Design and Synthesis of a Series of (2R)-N4-Hydroxy-2-(3-hydroxybenzyl)-N- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden- 1-yl]butanediamide Derivatives as Potent, Selective, and Orally Bioavailable Aggrecanase Inhibitors
- 19 September 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (21) , 3347-3350
- https://doi.org/10.1021/jm015533c
Abstract
A pharmacophore model of the P1‘ site, specific for aggrecanase, was defined using the specificity studies of the matrix metalloproteinases and the similar biological activity of aggrecanase and MMP-8. Incorporation of the side chain of a tyrosine residue into compound 1 as the P1‘ group provided modest selectivity for aggrecanase over MMP-1, -2, and -9. A cis-(1S)(2R)-amino-2-indanol scaffold was incorporated as a tyrosine mimic (P2‘) to conformationally constrain 2. Further optimization resulted in compound 11, a potent, selective, and orally bioavailable inhibitor of aggrecanase.Keywords
This publication has 17 references indexed in Scilit:
- X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysinProtein Science, 2001
- Heterocycle-based MMP Inhibitors with P2′ SubstituentsBioorganic & Medicinal Chemistry Letters, 2001
- The Thrombospondin Motif of Aggrecanase-1 (ADAMTS-4) Is Critical for Aggrecan Substrate Recognition and CleavageJournal of Biological Chemistry, 2000
- Aggrecanase: A Target for the Design of Inhibitors of Cartilage DegradationAnnals of the New York Academy of Sciences, 1999
- Generation and Characterization of AggrecanaseJournal of Biological Chemistry, 1999
- Degradation of cartilage aggrecan by collagenase‐3 (MMP‐13)FEBS Letters, 1996
- Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptidesBiopolymers, 1996
- Inhibition of Matrix Metalloproteinases by Hydroxamates Containing Heteroatom-Based Modifications of the P1' GroupJournal of Medicinal Chemistry, 1995
- Cell-mediated Catabolism of AggrecanPublished by Elsevier ,1995
- L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease InhibitorJournal of Medicinal Chemistry, 1994